Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.
We report 2 cases of leishmaniasis in patients with autoimmune rheumatic diseases in Greece. To assess trends in leishmaniasis reporting in this patient population, we searched the literature for similar reports from Europe. Reports increased during 2004-2008, especially for patients treated with anti-tumor necrosis factor agents.
Xynos
Ioannis D
ID
National and Kapodistrian University of Athens, Athens, Greece.
Tektonidou
Maria G
MG
Pikazis
Dimitrios
D
Sipsas
Nikolaos V
NV
D000368:Aged; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000150:complications / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D000069285:Infliximab; D007891:Leishmania / Q000302:isolation & purification; D007896:Leishmaniasis / Q000209:etiology* / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000150:complications / Q000276:immunology / Q000628:therapy*; D012307:Risk Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab